Levetiracetam 1a Pharma

Levetiracetam, the active ingredient in Levetiracetam 1a Pharma, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial onset seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑origin manufacturing facilities and ensuring quality compliance with EU pharmacopeial standards.

Levetiracetam is an anticonvulsant used to manage various seizure types in epilepsy.

Partial onset seizures: reduces seizure frequency and helps achieve seizure control. Generalized tonic‑clonic seizures: decreases occurrence of convulsive episodes. Myoclonic seizures: lessens rapid muscle jerks associated with epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Major depressive episodes - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Anaphylactic or severe hypersensitivity reactions - Multi‑organ involvement including hepatic or renal impairment

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal impairment: adjust dose based on renal function. - Mood changes: monitor for depression, anxiety, or suicidal ideation. - Discontinuation: avoid abrupt cessation to prevent seizure exacerbation. - Elderly patients: start at lower doses and titrate cautiously. - Pregnancy: safety category unknown; weigh benefits against potential risks. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Strong enzyme inducers (e.g., phenytoin, phenobarbital): can reduce levetiracetam levels. - Concomitant use with other antiepileptics that significantly alter renal clearance.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): may increase sedation. - Antidepressants or mood stabilizers: monitor for additive mood effects. - Antacids: may affect absorption; observe therapeutic response.